Plasma NfL levels could serve as a potential biomarker for neurodegeneration in the general population, helping to differentiate cognitive decline caused by AD from other conditions that lead to cognitive impairment during the prodromal stages in the general population [70]. This evidence concerns the gene NEFL and Cognitive impairment.